Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
PSMB1 Antibody
NCTP07781
Description: Rabbit polyclonal to human PSMB1
Application: ELISA, WB, IHC
Reactivity: Human
Catalog #: NCTP07781
Application: ELISA, WB, IHC
Reactivity: Human
Catalog #: NCTP07781
$380.00
1000 Items
Overview
| DESCRIPTION | |
| Species Reactivity | Human. Predicted reacts with rat, mouse. Other species not tested. |
| Isotype | IgG |
| Immunogen | Recombinant human PSMB1 protein 36-231aa |
| Accession # | P20618 |
| Alternative Names | Proteasome subunit beta type-1, Macropain subunit C5, Multicatalytic endopeptidase complex subunit C5, Proteasome component C5, Proteasome gamma chain, PSC5 |
| Purification | Purified by protein affinity column. |
| Formulation | Lyophilized with 1% BSA and 0.02% NaN3. |
| Size | 100µg/200µl |
| APPLICATION | |
| ELISA | 1:20,000-1:80,000 |
| Western Blot | 1:200-1:1,000 |
| Immunohistochemistry | 1:100-1:500 |
| - | For research use only. Optimal dilutions/concentrations should be determined by each laboratory for each application. |
| PREPARATION AND STORAGE | |
| Reconstitution | Reconstitute in 200µl of sterile H2O. |
| Storage | Shipped at ambient temperature. Store immediately at -20°C upon receipt. Avoid repeated freeze-thaw cycles. |
| REFERENCES | |
| - | Coiffier B, Li W, Henitz ED. et al. Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab. Clin. Cancer Res. 19 (9), 2551-2561 (2013). |